Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023

Dyne Therapeutics, Inc.

2023-Q1 EPS reported -$0.78

Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.
Cash $238.2M at March 31; raised $24.2M via ATM after quarter; funds through 2024.
R&D expenses $37.5M, up from $28.2M YoY.
Enrollment continues in ACHIEVE (DM1) and DELIVER (DMD) trials; initial data expected H2 2023.
DYNE-251 granted orphan drug and rare pediatric disease designations by FDA in March 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dyne Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share., EPS $0.78 per basic and diluted share.

Period: the quarter ended March 31, 2023
Net income: Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.
EPS: $0.78 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.